Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide. To assess the efficacy and safety of ofatumumab versus teriflunomide in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis Jg. 28; H. 10; S. 13524585221078825
Hauptverfasser: Gärtner, Jutta, Hauser, Stephen L, Bar-Or, Amit, Montalban, Xavier, Cohen, Jeffrey A, Cross, Anne H, Deiva, Kumaran, Ganjgahi, Habib, Häring, Dieter A, Li, Bingbing, Pingili, Ratnakar, Ramanathan, Krishnan, Su, Wendy, Willi, Roman, Kieseier, Bernd, Kappos, Ludwig
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.09.2022
Schlagworte:
Relapsing multiple sclerosis
treatment-naive
neurofilament light chain
no evidence of disease activity
progression independent of relapse activity
recently diagnosed
ISSN:1477-0970, 1477-0970
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide. To assess the efficacy and safety of ofatumumab versus teriflunomide in recently diagnosed, treatment-naive (RDTN) participants from ASCLEPIOS. Participants were randomized to receive ofatumumab (20 mg subcutaneously every 4 weeks) or teriflunomide (14 mg orally once daily) for up to 30 months. Endpoints analysed post hoc in the protocol-defined RDTN population included annualized relapse rate (ARR), confirmed disability worsening (CDW), progression independent of relapse activity (PIRA) and adverse events. Data were analysed from 615 RDTN participants (ofatumumab:  = 314; teriflunomide:  = 301). Compared with teriflunomide, ofatumumab reduced ARR by 50% (rate ratio (95% confidence interval (CI)): 0.50 (0.33, 0.74);  < 0.001), and delayed 6-month CDW by 46% (hazard ratio (HR; 95% CI): 0.54 (0.30, 0.98);  = 0.044) and 6-month PIRA by 56% (HR: 0.44 (0.20, 1.00);  = 0.049). Safety findings were manageable and consistent with those of the overall ASCLEPIOS population. The favourable benefit-risk profile of ofatumumab versus teriflunomide supports its consideration as a first-line therapy in RDTN patients.ASCLEPIOS I and II are registered at ClinicalTrials.gov (NCT02792218 and NCT02792231).
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1477-0970
1477-0970
DOI:10.1177/13524585221078825